ArticleBMC women's health2026
Hysteroscopic myomectomy for FIGO type 3 uterine fibroids with diameter not less than 5 cm: a retrospective, single-center study of eighteen cases.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHysteroscopic myomectomy is a preferred treatment for women requiring future fertility. While it was difficult to manage large submucosal fibroids or deep intramural invasion myomas with hysteroscopic approaches. We conducted this study to explore the feasibility of hysteroscopic removal of large sized (≥ 5 cm) FIGO type 3 fibroids with deep intramural invasion that are difficult to manage with one-step hysteroscopy by "downgrading" technique.
methodsThis retrospective study included of hysteroscopic myomectomy from February 2023 to September 2025 in an academic university hospital. The removal of large type 3 myomas was typically not less than 5 cm in maximum diameter. The clinical characteristics, details of the surgery and postoperative follow-up were collected for retrospective analysis.
resultsA total of eighteen patients were included. The primary maximum diameter of fibroids ranges from 5 to 9.5 cm (median size was 6.5 cm) and ten of them was 6 cm or larger. 77.8% cases scored above 6 according to the classification of the STEPW classifications. Mean hysteroscopic operating time was 41.7 min. The perfusion fluid deficit was between 300 and 2,500 mL. The lowest blood potassium levels ranged from 2.11 to 3.82 mmol/ml. The One-step Hysteroscopic resection was performed in sixteen cases, 88.9% of patients. One case had successfully removed the residual fibroid through another hysteroscopic surgery six weeks after surgery, and another patient refused to receive a reoperation. All patients exhibited stable vital signs intraoperatively and postoperatively. The menstruation was recovered in all patients after the procedure. After 3 to 34 months of follow-up, there was no evidence of the recurrence in all but one patient who lost to follow-up at 1 year postoperatively. Notably, three patient achieved pregnancy spontaneously and two of them successfully delivered a healthy baby.
conclusionsHysteroscopic resection with "downgrading" technique is a potential alternative approach for women with large (≥ 5 cm) FIGO type 3 fibroids. However, careful execution in a proficient hysteroscopic center is essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.